R01HL155547

MYCOBACTERIAL LUNG DISEASES IN VIRGINIA: SEQUENCING AND CLINICAL DETERMINANTS OF RELAPSE AND OUTCOME - PROJECT SUMMARY / ABSTRACT

NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASES, PRIMARILY DUE TO M. AVIUM COMPLEX (MAC), IS AN INCREASING CLINICAL PROBLEM NATIONWIDE AND NOW OVERTAKES DOMESTIC TB IN TERMS OF MORBIDITY AND MORTALITY. IT IS ALSO HARDER TO TREAT AND RESULTS IN POORER OUTCOMES DESPITE LONGER DRUG REGIMENS.

IN THIS CONTEXT NIH ISSUED A NOTICE AI-17-016 TO REQUEST APPLICATIONS FOR NTM DISEASES. HERE WE PRESENT A PROPOSAL FROM THE UNIVERSITY OF VIRGINIA, WITH COLLABORATORS AT THE VIRGINIA DEPARTMENT OF HEALTH AND VIRGINIA TECH, THAT ADDRESSES MANY OF THE NEEDS THAT WERE CITED.

FIRST, WE WILL PERFORM WHOLE GENOME SEQUENCING OF MAC ISOLATES FROM ALL OF OUR STATE'S MAC LUNG DISEASE PATIENTS TO DISCERN RELAPSE VERSUS REINFECTION AND THE ENVIRONMENTAL SOURCES OF ACQUISITION. SECOND WE WILL UTILIZE A STATE-WIDE COHORT OF NEW MAC LUNG DISEASE PATIENTS TO CORRELATE CLINICAL OUTCOMES WITH MAC SPECIES, DRUG SUSCEPTIBILITY, SERUM DRUG LEVELS, AND BIOFILM BIOASSAY.

INNOVATION INCLUDES THE USE OF A STATE-WIDE EPIDEMIOLOGICAL COHORT, EXQUISITE RESOLUTION WITH EXTENSIVE PRELIMINARY DATA OF WHOLE GENOME SEQUENCING TO DISCERN SPECIES AND MIXED INFECTIONS, A COMPREHENSIVE STATE-WIDE SERUM DRUG MONITORING PROGRAM (AS WE HAVE DONE ALREADY FOR TB), AND EXPERTISE IN MOLECULAR DIAGNOSTICS AND GENOTYPIC-PHENOTYPIC CORRELATIONS.

IN SUM, FOR THIS MOST VEXING CLINICAL PROBLEM OF MAC LUNG DISEASE WE BRING TO BEAR EXTENSIVE PRELIMINARY DATA, UNIQUE EXPERTISE, INNOVATIVE TECHNOLOGY, COHESIVE COLLABORATIONS, AND SYNERGISTIC AIMS.

Rector & Visitors Of The University Of Virginia

THE DIVISION OF LUNG DISEASES SUPPORTS RESEARCH AND RESEARCH TRAINING ON THE CAUSES, DIAGNOSIS, PREVENTION, AND TREATMENT OF LUNG DISEASES AND SLEEP DISORDERS. RESEARCH IS FUNDED THROUGH INVESTIGATOR-INITIATED AND INSTITUTE-INITIATED GRANT PROGRAMS AND THROUGH CONTRACT PROGRAMS IN AREAS INCLUDING ASTHMA, BRONCHOPULMONARY DYSPLASIA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CYSTIC FIBROSIS, RESPIRATORY NEUROBIOLOGY, SLEEP AND CIRCADIAN BIOLOGY, SLEEP-DISORDERED BREATHING, CRITICAL CARE AND ACUTE LUNG INJURY, DEVELOPMENTAL BIOLOGY AND PEDIATRIC PULMONARY DISEASES, IMMUNOLOGIC AND FIBROTIC PULMONARY DISEASE, RARE LUNG DISORDERS, PULMONARY VASCULAR DISEASE, AND PULMONARY COMPLICATIONS OF AIDS AND TUBERCULOSIS. THE DIVISION IS RESPONSIBLE FOR MONITORING THE LATEST RESEARCH DEVELOPMENTS IN THE EXTRAMURAL SCIENTIFIC COMMUNITY AS WELL AS IDENTIFYING RESEARCH GAPS AND NEEDS, OBTAINING ADVICE FROM EXPERTS IN THE FIELD, AND IMPLEMENTING PROGRAMS TO ADDRESS NEW OPPORTUNITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.

93.837 - Cardiovascular Diseases Research

National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]

Virginia United States

State-Wide

Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-19-056)

Amendment Since initial award the total obligations have increased 349% from $721,114 to $3,237,702.